These trials have fundamentally shifted MASLD treatment toward targeting metabolic dysfunction, exemplified by semaglutide’s success in achieving significant NASH resolution through weight loss and improved insulin sensitivity. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.